NO20052516L - Fremgangsmate for a behandle insulinresistens, diabetes som inntrer i voksen alder og metabolsk syndrom X - Google Patents
Fremgangsmate for a behandle insulinresistens, diabetes som inntrer i voksen alder og metabolsk syndrom XInfo
- Publication number
- NO20052516L NO20052516L NO20052516A NO20052516A NO20052516L NO 20052516 L NO20052516 L NO 20052516L NO 20052516 A NO20052516 A NO 20052516A NO 20052516 A NO20052516 A NO 20052516A NO 20052516 L NO20052516 L NO 20052516L
- Authority
- NO
- Norway
- Prior art keywords
- adulthood
- metabolic syndrome
- insulin resistance
- procedures
- treating insulin
- Prior art date
Links
- 206010022489 Insulin Resistance Diseases 0.000 title abstract 2
- 208000001145 Metabolic Syndrome Diseases 0.000 title abstract 2
- 201000010390 abdominal obesity-metabolic syndrome 1 Diseases 0.000 title abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 208000011661 metabolic syndrome X Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 2
- 102000004420 Creatine Kinase Human genes 0.000 abstract 3
- 108010042126 Creatine kinase Proteins 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 239000002502 liposome Substances 0.000 abstract 2
- 239000000725 suspension Substances 0.000 abstract 2
- 108010082126 Alanine transaminase Proteins 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 108010028554 LDL Cholesterol Proteins 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 108010033266 Lipoprotein(a) Proteins 0.000 abstract 1
- 102000057248 Lipoprotein(a) Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42104202P | 2002-10-25 | 2002-10-25 | |
| PCT/US2003/033649 WO2004039430A2 (fr) | 2002-10-25 | 2003-10-23 | Procede de traitement de la resistance a l'insuline, du diabete chez l'adulte et du syndrome x metabolique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20052516D0 NO20052516D0 (no) | 2005-05-25 |
| NO20052516L true NO20052516L (no) | 2005-05-25 |
Family
ID=32230213
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20052516A NO20052516L (no) | 2002-10-25 | 2005-05-25 | Fremgangsmate for a behandle insulinresistens, diabetes som inntrer i voksen alder og metabolsk syndrom X |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20050287197A1 (fr) |
| EP (1) | EP1585499A2 (fr) |
| JP (1) | JP2006506403A (fr) |
| KR (1) | KR20050055785A (fr) |
| CN (1) | CN1731982A (fr) |
| AU (1) | AU2003286633A1 (fr) |
| BR (1) | BR0314907A (fr) |
| CA (1) | CA2501601C (fr) |
| IS (1) | IS7800A (fr) |
| MX (1) | MXPA05004287A (fr) |
| NO (1) | NO20052516L (fr) |
| RU (1) | RU2005115956A (fr) |
| WO (1) | WO2004039430A2 (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9737511B2 (en) * | 2004-05-24 | 2017-08-22 | Geoffrey C. GURTNER | Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux |
| CA2568134A1 (fr) | 2004-05-24 | 2005-12-08 | New York University | Methode de traitement ou de prevention d'effets pathologiques d'augmentations aigues de l'hyperglycemie et/ou d'augmentations aigues de flux d'acides gras libres |
| CN1891229B (zh) * | 2005-07-07 | 2010-05-05 | 北京华安佛医药研究中心有限公司 | 预防或治疗代谢综合征的药物制剂 |
| US20090117198A1 (en) | 2006-05-31 | 2009-05-07 | Hiroshi Kawakami | Visceral fat accumulation inhibitor, and agent for promoting the increase in and/or inhibiting the decrease in blood adiponectin level |
| US20090270420A1 (en) * | 2006-06-01 | 2009-10-29 | Sobel Burton E | Methods for inhibiting cardiac pai-1 |
| WO2008039266A2 (fr) * | 2006-07-28 | 2008-04-03 | Beckman Coulter, Inc. | Agents stabilisants et ligands de capture destinés à être utilisés dans des dosages mesurant des concentrations d'analytes |
| WO2008104084A1 (fr) * | 2007-03-01 | 2008-09-04 | Liponex, Inc. | Phospholipides contenant du linoléoyle et méthodes d'utilisation de ceux-ci |
| US20090054372A1 (en) * | 2007-03-21 | 2009-02-26 | Goldsmith Ivan L | Combination therapy for weight loss |
| US8410085B2 (en) | 2007-11-16 | 2013-04-02 | Baylor College Of Medicine | Phospholipid compositions and uses thereof |
| KR100922061B1 (ko) * | 2007-12-12 | 2009-10-16 | 주식회사 포스코 | 극저탄소 페라이트계 스테인리스강 제조방법 |
| WO2010039040A1 (fr) * | 2008-09-30 | 2010-04-08 | Epax As | Composition comprenant au moins un agoniste de ppar et un composant phospholipidique |
| US10098857B2 (en) | 2008-10-10 | 2018-10-16 | The Board Of Trustees Of The Leland Stanford Junior University | Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds |
| US8337835B2 (en) | 2009-04-10 | 2012-12-25 | Washington University | Use of an endogenous ligand for peroxisome proliferator activated receptor alpha to treat liver disorders |
| RU2483748C2 (ru) * | 2011-04-15 | 2013-06-10 | Леонид Леонидович Клопотенко | Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде пластыря |
| RU2483749C2 (ru) * | 2011-04-15 | 2013-06-10 | Леонид Леонидович Клопотенко | Фармацевтическая композиция, содержащая инсулин и липосомы, для местного применения в виде биопленки |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| CN102793668A (zh) * | 2012-08-30 | 2012-11-28 | 绍兴文理学院 | 一种ps-脂质体 |
| CN102793669A (zh) * | 2012-08-30 | 2012-11-28 | 绍兴文理学院 | 一种ps-脂质体合成工艺 |
| CN102793670A (zh) * | 2012-08-30 | 2012-11-28 | 绍兴文理学院 | 一种ps-脂质体及其合成工艺 |
| CN105934520A (zh) * | 2014-01-31 | 2016-09-07 | 伊克斯塞拉有限公司 | 作为生物标志物的共价键代谢物 |
| US11234454B2 (en) | 2016-12-15 | 2022-02-01 | Société des Produits Nestlé S.A. | Compositions and methods that modulate cholesterol in a companion animal |
| US11331288B2 (en) | 2017-09-14 | 2022-05-17 | The Board Of Trustees Of The Leland Stanford Junior University | Conditioning irradiated tissue for increasing vascularity |
| CN112533494A (zh) * | 2018-06-22 | 2021-03-19 | 方塔拉合作集团有限公司 | 使用极性脂质治疗或预防妊娠期糖尿病 |
| US11041847B1 (en) | 2019-01-25 | 2021-06-22 | Ixcela, Inc. | Detection and modification of gut microbial population |
| US20220288130A1 (en) * | 2019-08-14 | 2022-09-15 | University Of Louisville Research Foundation, Inc. | Compositions and methods for diagnosis and treatment of metabolic diseases and disorders |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6013619A (en) * | 1988-01-06 | 2000-01-11 | The Scripps Research Institute | Pulmonary surfactants and therapeutic uses, including pulmonary lavage |
| US5451569A (en) * | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US6261597B1 (en) * | 1995-08-31 | 2001-07-17 | Seymour J. Kurtz | Method for treating periodontal disease |
| US20020055512A1 (en) * | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
-
2003
- 2003-10-23 CA CA002501601A patent/CA2501601C/fr not_active Expired - Fee Related
- 2003-10-23 WO PCT/US2003/033649 patent/WO2004039430A2/fr not_active Ceased
- 2003-10-23 EP EP03777839A patent/EP1585499A2/fr not_active Withdrawn
- 2003-10-23 JP JP2004548441A patent/JP2006506403A/ja not_active Abandoned
- 2003-10-23 AU AU2003286633A patent/AU2003286633A1/en not_active Abandoned
- 2003-10-23 US US10/530,281 patent/US20050287197A1/en not_active Abandoned
- 2003-10-23 MX MXPA05004287A patent/MXPA05004287A/es unknown
- 2003-10-23 BR BR0314907-2A patent/BR0314907A/pt not_active IP Right Cessation
- 2003-10-23 KR KR1020057007091A patent/KR20050055785A/ko not_active Withdrawn
- 2003-10-23 CN CNA2003801075433A patent/CN1731982A/zh active Pending
- 2003-10-23 RU RU2005115956/14A patent/RU2005115956A/ru not_active Application Discontinuation
-
2005
- 2005-04-14 IS IS7800A patent/IS7800A/is unknown
- 2005-05-25 NO NO20052516A patent/NO20052516L/no not_active Application Discontinuation
-
2007
- 2007-02-06 US US11/702,526 patent/US7807193B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004039430A2 (fr) | 2004-05-13 |
| NO20052516D0 (no) | 2005-05-25 |
| US20070141136A1 (en) | 2007-06-21 |
| CA2501601C (fr) | 2008-12-30 |
| BR0314907A (pt) | 2005-08-02 |
| KR20050055785A (ko) | 2005-06-13 |
| CN1731982A (zh) | 2006-02-08 |
| AU2003286633A1 (en) | 2004-05-25 |
| JP2006506403A (ja) | 2006-02-23 |
| US7807193B2 (en) | 2010-10-05 |
| US20050287197A1 (en) | 2005-12-29 |
| IS7800A (is) | 2005-04-14 |
| CA2501601A1 (fr) | 2004-05-13 |
| WO2004039430A3 (fr) | 2004-09-23 |
| EP1585499A2 (fr) | 2005-10-19 |
| MXPA05004287A (es) | 2005-08-03 |
| RU2005115956A (ru) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ristic et al. | Improved glycaemic control with dipeptidyl peptidase‐4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response | |
| Heise et al. | Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: a phase 1 randomized, crossover study | |
| WO2004039430A3 (fr) | Procede de traitement de la resistance a l'insuline, du diabete chez l'adulte et du syndrome x metabolique | |
| He et al. | Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT | |
| Kawaguchi et al. | Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec in patients with type 2 diabetes: a randomized, open‐label, cross‐over study using continuous glucose monitoring profiles | |
| Ahrén et al. | Twelve-and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes | |
| Pan et al. | Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24‐week, double‐blind, randomized trial | |
| Hermansen et al. | Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin | |
| Salehi et al. | Effect of endogenous GLP-1 on insulin secretion in type 2 diabetes | |
| Schweizer et al. | Comparison between vildagliptin and metformin to sustain reductions in HbA1c over 1 year in drug‐naïve patients with Type 2 diabetes | |
| Bunck et al. | Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes | |
| Li et al. | Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of β-cell function | |
| George et al. | Potential role of non‐insulin adjunct therapy in type 1 diabetes | |
| Salsali et al. | Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials | |
| Kikuchi et al. | Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with type 2 diabetes mellitus | |
| Zenari et al. | What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus? | |
| McKenna et al. | Acute hyperglycaemia causes elevation in plasma atrial natriuretic peptide concentrations in type 1 diabetes mellitus | |
| Henry et al. | Effects of saxagliptin on β‐cell stimulation and insulin secretion in patients with type 2 diabetes | |
| JP2012502059A5 (fr) | ||
| Garg et al. | Liraglutide acutely suppresses glucagon, lipolysis and ketogenesis in type 1 diabetes | |
| Thethi et al. | Consequences of delayed pump infusion line change in patients with type 1 diabetes mellitus treated with continuous subcutaneous insulin infusion | |
| Strowig et al. | Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus | |
| Chase et al. | Pramlintide Lowered Glucose Excursions and Was Well-Tolerated in Adolescents with Type 1 Diabetes: Results from a Randomized, Single-Blind, Placebo-Controlled, Crossover Study/STI | |
| Bailey et al. | Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes | |
| Scheen | Treatment of diabetes in patients with severe obesity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |